A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; SON 1010 (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Proof of concept
Sponsors Sonnet BioTherapeutics Holdings, Inc

04 Apr 2025 According to Sonnet BioTherapeutics Holdings media release,, announced positive safety results of SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab in the Phase 1b/2a clinical trial in adult patients with advanced solid tumors or platinum-resistant ovarian cancer (PROC) (the SB221 study).
04 Apr 2025 Results published in the Sonnet BioTherapeutics Holdings media release
17 Dec 2024 According to Sonnet BioTherapeutics Holdings media release, RP2D & Topline Efficacy Data is anticipated in H2 calendar year 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com